World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
45509
World Ranking
18230
National Ranking
9092

Overview

Joachim von Pawel is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine with a particular concentration on Oncology and Pulmonary and Respiratory Medicine. Additional subfields include Molecular Biology, Surgery, and Epidemiology, reflecting a broad interdisciplinary approach within biomedical sciences.

Their work encompasses a variety of topics, notably in lung cancer research and treatment, as well as studies related to cholangiocarcinoma and gallbladder cancer. Specific research themes include:

  • Lung Cancer Research Studies
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Glycosylation and Glycoproteins Research
  • RNA modifications and cancer
  • Neuroendocrine Tumor Research Advances

Their frequently published work appears mainly in the following venues:

  • Journal of Clinical Oncology (2 publications)
  • Tumor Biology (2 publications)
  • Diagnostics (1 publication)
  • UNC Libraries (1 publication)

Recent publications provide insights into lung cancer treatment protocols, biomarkers, and diagnostic approaches. These include:

  • Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer, 2023, Journal of Clinical Oncology
  • Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy, 2023, Journal of Clinical Oncology
  • Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients, 2021, Diagnostics
  • Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations, 2024, Tumor Biology
  • Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer, 2023, Tumor Biology

Joachim von Pawel collaborates frequently with several researchers in the oncology field. Notable frequent co-authors include Stefan Holdenrieder, Christian Manegold, U. Gatzemeier, Filippo de Marinis, and Alexander Rupp.

Best Publications

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma

  • Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

    Nasser Hanna;Frances A. Shepherd;Frank V. Fossella;Jose R. Pereira

  • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

    Nick Thatcher;Alex Chang;Purvish Parikh;José Rodrigues Pereira

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

    Martin Reck;Joachim von Pawel;Petr Zatloukal;Rodryg Ramlau

  • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

    Robert Pirker;Jose R. Pereira;Aleksandra Szczesna;Joachim von Pawel

  • Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

    Frank Fossella;Jose R. Pereira;Joachim von Pawel;Anna Pluzanska

  • Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

    Ulrich Gatzemeier;Anna Pluzanska;Aleksandra Szczesna;Eckhard Kaukel

  • Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

    Joachim von Pawel;Joan H. Schiller;Frances A. Shepherd;Scott Z. Fields

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

    Alan B. Sandler;J. Nemunaitis;C. Denham;J. Von Pawel

  • Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

    M. Reck;J Von Pawel;P. Zatloukal;R. Ramlau

  • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

    Robert Pirker;Jose R. Pereira;Joachim Von Pawel;Maciej Krzakowski

  • Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

    Giorgio Scagliotti;Silvia Novello;Joachim von Pawel;Martin Reck

  • Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Andrea Bezjak;Dongsheng Tu;Lesley Seymour;Gary Clark

  • Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Joachim von Pawel;Edward G. Garmey;Wallace L. Akerley

  • Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

    John R. Eckardt;Joachim von Pawel;Jean-Louis Pujol;Zsolt Papai

  • Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

    Ramaswamy Govindan;Aleksandra Szczesna;Myung Ju Ahn;Claus Peter Schneider

  • Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

    Primo N Lara;Jean Yves Douillard;Kazuhiko Nakagawa;Joachim Von Pawel

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Giorgio V. Scagliotti
Giorgio V. Scagliotti University of Turin
Silvia Novello
Silvia Novello University of Turin
Igor Bondarenko
Igor Bondarenko Ministry of Internal Affairs
Jean-Yves Douillard
Jean-Yves Douillard European Society for Medical Oncology
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
David R. Spigel
David R. Spigel Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a wide range of online degrees and healthcare career pathways. Many students begin their journey as registered nurses and later consider further specializations. For those aiming to become a family nurse practitioner without stepping away from their current roles, rn to fnp programs offer a flexible bridge to advanced practice.

An increasing number of students are also drawn to fields like nutrition. If you are passionate about promoting health and wellness, an online nutritionist degree can be a rewarding path and often complements pre-med and allied health studies.

For nurses seeking to expand their qualifications, some universities now offer online rn to bsn no clinicals programs, making it even more convenient for working professionals to upgrade their skills without extra on-site commitments.

Hospital management is another in-demand pathway. If you are a working adult exploring the administrative side of healthcare, you might wonder whats the best online mha program for working adults. These programs are designed to fit busy schedules while offering essential leadership and management training.

Best Scientists Citing Joachim von Pawel

Trending Scientists

Recently Published Articles